
Please try another search
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Name | Age | Since | Title |
---|---|---|---|
Jay Goodman | - | 2024 | Independent Director |
Jagdeep Nanchahal | - | - | Co-Founder & Chairman of Clinical Advisory Board |
Sallie Lamb | - | 2022 | Member of Scientific Advisory Board |
Kevin J. Tracey | - | 2022 | Member of Scientific Advisory Board |
Irene Tracey | - | 2022 | Member of Scientific Advisory Board |
Chas Bountra | - | 2022 | Member of Scientific Advisory Board |
Lawrence Steinman | 77 | 2019 | Co-Founder & Director |
Lloyd Blair Jordan | 55 | 2024 | CEO & Director |
Ryan Lewis Smith | 42 | 2024 | Lead Independent Director |
Stephen H. Shoemaker | 64 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review